GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (STU:NG9) » Definitions » Shiller PE Ratio

NeoGenomics (STU:NG9) Shiller PE Ratio : (As of Jun. 10, 2024)


View and export this data going back to 2016. Start your Free Trial

What is NeoGenomics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


NeoGenomics Shiller PE Ratio Historical Data

The historical data trend for NeoGenomics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics Shiller PE Ratio Chart

NeoGenomics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NeoGenomics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NeoGenomics's Shiller PE Ratio

For the Diagnostics & Research subindustry, NeoGenomics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeoGenomics's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where NeoGenomics's Shiller PE Ratio falls into.



NeoGenomics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

NeoGenomics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, NeoGenomics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.193/131.7762*131.7762
=-0.193

Current CPI (Mar. 2024) = 131.7762.

NeoGenomics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.007 100.560 0.009
201409 -0.008 100.428 -0.010
201412 0.016 99.070 0.021
201503 -0.009 99.621 -0.012
201506 -0.003 100.684 -0.004
201509 -0.002 100.392 -0.003
201512 -0.028 99.792 -0.037
201603 -0.063 100.470 -0.083
201606 -0.062 101.688 -0.080
201609 -0.062 101.861 -0.080
201612 -0.171 101.863 -0.221
201703 -0.047 102.862 -0.060
201706 -0.027 103.349 -0.034
201709 -0.076 104.136 -0.096
201712 0.025 104.011 0.032
201803 -0.024 105.290 -0.030
201806 0.060 106.317 0.074
201809 0.017 106.507 0.021
201812 0.003 105.998 0.004
201903 -0.027 107.251 -0.033
201906 0.018 108.070 0.022
201909 0.018 108.329 0.022
201912 0.054 108.420 0.066
202003 -0.063 108.902 -0.076
202006 -0.053 108.767 -0.064
202009 0.017 109.815 0.020
202012 0.107 109.897 0.128
202103 -0.160 111.754 -0.189
202106 0.490 114.631 0.563
202109 -0.145 115.734 -0.165
202112 -0.301 117.630 -0.337
202203 -0.363 121.301 -0.394
202206 -0.265 125.017 -0.279
202209 -0.303 125.227 -0.319
202212 -0.170 125.222 -0.179
202303 -0.233 127.348 -0.241
202306 -0.175 128.729 -0.179
202309 -0.141 129.860 -0.143
202312 -0.101 129.419 -0.103
202403 -0.193 131.776 -0.193

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


NeoGenomics  (STU:NG9) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


NeoGenomics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of NeoGenomics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NeoGenomics (STU:NG9) Business Description

Traded in Other Exchanges
Address
9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.

NeoGenomics (STU:NG9) Headlines

No Headlines